Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO) and Xenon (XENE)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Lexeo Therapeutics, Inc. (LXEO – Research Report) and Xenon (XENE – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Lexeo Therapeutics, Inc. (LXEO)
In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Lexeo Therapeutics, Inc., with a price target of $13.00. The company’s shares closed last Thursday at $9.47.
According to TipRanks.com, Kapoor is a 4-star analyst with an average return of
Lexeo Therapeutics, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $20.29.
See today’s best-performing stocks on TipRanks >>
Xenon (XENE)
J.P. Morgan analyst Tessa Romero maintained a Buy rating on Xenon today and set a price target of $62.00. The company’s shares closed last Thursday at $41.22.
According to TipRanks.com, Romero is a 5-star analyst with an average return of
Currently, the analyst consensus on Xenon is a Strong Buy with an average price target of $54.09, representing a 29.4% upside. In a report issued on December 31, Chardan Capital also initiated coverage with a Buy rating on the stock with a $55.00 price target.
